Atara Biotherapeutics (ATRA) Income from Continuing Operations (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Income from Continuing Operations came in at 4145000.0 in Q1 2026, down 110.91% YoY from 38010000.0 in Q1 2025, and down 22.34% on a QoQ basis from 3388000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Income from Continuing Operations data on file, last reported at 4145000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 110.91% year-over-year to 4145000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9449000.0 (up 39.59% YoY) and the FY2025 annual result came in at 32706000.0, up 138.3% from the prior year.
- Income from Continuing Operations declined to 4145000.0 in Q1 2026, from 3388000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 38010000.0 in Q1 2025 to a low of 88105000.0 in Q1 2022.
- A 5-year average of 33015882.35 and a median of 21909000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations tumbled 485.08% — and 2025, when it jumped 219.71%.
- Tracing ATRA's Income from Continuing Operations over 5 years: stood at 74572000.0 in 2022, then climbed by 18.94% to 60450000.0 in 2023, then jumped by 79.0% to 12693000.0 in 2024, then jumped by 73.31% to 3388000.0 in 2025, then dropped by 22.34% to 4145000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 4145000.0 (Q1 2026), 3388000.0 (Q4 2025), and 4303000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | -4.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.83 Mn |
| Mar 31, 2026 | -4.15 Mn |
| Dec 31, 2025 | -3.39 Mn |
| Sep 30, 2025 | -4.30 Mn |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | 38.01 Mn |
| Dec 31, 2024 | -12.69 Mn |
| Sep 30, 2024 | -21.91 Mn |
| Jun 30, 2024 | -19.05 Mn |
| Mar 31, 2024 | -31.75 Mn |
| Dec 31, 2023 | -60.45 Mn |
| Sep 30, 2023 | -69.80 Mn |
| Jun 30, 2023 | -71.11 Mn |
| Mar 31, 2023 | -74.77 Mn |
| Dec 31, 2022 | -74.57 Mn |
| Sep 30, 2022 | -84.09 Mn |
| Jun 30, 2022 | 18.47 Mn |
| Mar 31, 2022 | -88.11 Mn |
| Dec 31, 2021 | -93.56 Mn |
| Sep 30, 2021 | -84.66 Mn |